Aug 12, 2020
LASEROPTEK Co. Ltd., Announces U.S. Launch of PALLAS, First-of-its-Kind Solid State UVB Medical Dermatology Laser
Jun 12, 2020
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA(TM) (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Jun 12, 2020
AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
Jun 11, 2020
Sun Pharma Plans to Present Clinical Insights from 25 Data Abstracts Across its Dermatology Portfolio at the 2020 AAD Virtual Meeting Experience
Jun 03, 2020
New First-in-Class Phase 3 TREMFYA® (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52
Jun 03, 2020
EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
Jun 02, 2020
The Global Psoriasis Therapeutics Market is expected to grow from USD 14,236.13 Million in 2018 to USD 26,125.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 9.06%
May 15, 2020
Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms
May 07, 2020
Global Corticosteroids Therapy Industry & COVID-19, Forecast to 2030
Apr 29, 2020
FDA Approves Ortho Dermatologics' Labeling For JUBLIA® (efinaconazole) Topical Solution, 10%, In Patients As Young As Six Years Old
Apr 27, 2020
American Skin Association Announces New Board Member Mark Lebwohl, MD
Apr 15, 2020
Dermatologicals Market to Reach $36.20 Bn, Globally, by 2026 at 10.9% CAGR: Allied Market Research
Apr 09, 2020
Global Dermatologicals Market is Expected to Reach $36.2 Billion by 2026
Apr 06, 2020
The Lancet Simultaneously Publishes Two Phase 3 Studies Detailing Comprehensive Efficacy and Safety of TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, in Psoriatic Arthritis
Mar 31, 2020
3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2%
Mar 30, 2020
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Mar 17, 2020
US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market
Mar 12, 2020
International Psoriasis Council Statement On The Coronavirus (COVID-19) Outbreak
Mar 09, 2020
The psoriatic arthritis treatment market was valued at $7,860 million in 2018, and is estimated to reach at $13,744 million by 2026, registering a CAGR of 7.2% from 2019 to 2026
Mar 06, 2020
Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028